In This Article:
Release Date: May 08, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
TransMedics Group Inc (NASDAQ:TMDX) reported a record total revenue of $143.5 million for Q1 2025, representing a 48% year-over-year growth.
-
The company achieved a significant improvement in gross margins, reaching 61.5%, up from 59% in the previous quarter.
-
TransMedics Group Inc (NASDAQ:TMDX) saw a strong increase in transplant services revenue, up 56% year-over-year, driven by higher utilization of their OCS NOP platform.
-
The company reported an operating profit of $27.4 million, which is a substantial increase from $8.6 million in Q4 2024.
-
TransMedics Group Inc (NASDAQ:TMDX) raised its full-year 2025 revenue guidance to between $565 million and $585 million, indicating confidence in continued growth.
Negative Points
-
The company acknowledged potential variability and seasonality in quarterly performance, which could impact results in upcoming quarters.
-
There are concerns about the potential impact of geopolitical, macroeconomic, and tariff policies on the business, although currently deemed minimal.
-
Service gross margins declined by 632 basis points year-over-year, primarily due to the higher proportion of aviation business.
-
The company faces potential competition in the liver transplant market, with new entrants expected later in the year.
-
There is uncertainty regarding the precise launch timing of new clinical programs, as it depends on FDA approval and other regulatory processes.
Q & A Highlights
Q: Can you break down the drivers of your growth in liver transplants and what you're seeing so far in April? A: (CEO) We are seeing growth across both DVD and DCD liver transplants, with increased utilization and momentum. We believe we have the best platform for liver preservation, and upcoming publications will support this with data and evidence. As for April, we are confident in our guidance, considering potential headwinds and variability throughout the year.
Q: How do you anticipate product and service margins could be impacted during the heart and lung clinical trials? A: (CEO) We expect to incur product revenue during the trials and are confident in generating service revenue on the OCS arm. However, we are still discussing the service revenue expectations for the control arm and will provide more details once the trial design is finalized and approved by the FDA.
Q: With competitors entering the liver market, what gives you confidence in your guidance and any potential impact in the second half of the year? A: (CEO) Our liver platform delivers the best results in liver transplantation history, providing cost-efficient and convenient solutions. We stand by our product and data, and upcoming publications will highlight our value. We are committed to making OCS liver the standard of care in liver transplantation globally.